HCPCS Level II code J0491 denotes the billed drug product anifrolumab-fnia at a unit of 1 mg. As a HCPCS code for a biologic injection, it matters nationally because it is the standardized identifier used by payers and providers for claims, coverage determinations, and payment processing for this specialty therapeutic. Accurate coding of biologic units affects patient cost-sharing, utilization tracking, and pharmacy/medical benefit delineation.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0491 represents clinically and operationally, common sites where the product is delivered, and the typical considerations payers apply when adjudicating claims for unit-priced biologic HCPCS codes. The publication outlines benchmarks and payment context, summarizes any relevant policy updates impacting coverage and billing workflows, and provides clinical context for where anifrolumab-fnia is used.

This summary is intended for national audiences involved in coding, billing, revenue cycle management, and payer policy. Data not provided in the input (such as associated taxonomies, specific ICD-10 pairings, and payer-specific fee schedules) is explicitly noted as unavailable where relevant in the full publication.